123 related articles for article (PubMed ID: 38342654)
1. Reducing the demand for magnetic resonance imaging scans and prostate biopsies during the early detection of clinically significant prostate cancer: Applying the Barcelona risk-stratified pathway in Catalonia.
Morote J; Borque-Fernando Á; Esteban LE; Picola N; Muñoz-Rodriguez J; Paesano N; Ruiz-Plazas X; Muñoz-Rivero MV; Celma A; García-de Manuel G; Miró B; Abascal JM; Servian P
Urol Oncol; 2024 Apr; 42(4):115.e1-115.e7. PubMed ID: 38342654
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of prostate cancer identified by transperineal standard template biopsy in men with nonsuspicious multiparametric magnetic resonance imaging.
Dahl DM; Wu S; Lin SX; Hu M; Barney AA; Kim MM; Cornejo KM; Harisinghani MG; Feldman AS; Wu CL
Urol Oncol; 2024 Feb; 42(2):28.e21-28.e28. PubMed ID: 38182499
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.
Filson CP; Natarajan S; Margolis DJ; Huang J; Lieu P; Dorey FJ; Reiter RE; Marks LS
Cancer; 2016 Mar; 122(6):884-92. PubMed ID: 26749141
[TBL] [Abstract][Full Text] [Related]
4. Are magnetic resonance imaging and targeted biopsies needed in men with serum prostate-specific antigen over 10 ng/ml and an abnormal digital rectal examination?
Morote J; Picola N; Paesano N; Celma A; Muñoz-Rodriguez J; Asiain I; Ruiz-Plazas X; Muñoz-Rivero MV; de Manuel GG; Servian P; Abascal JM
Urol Oncol; 2023 Jul; 41(7):299-301. PubMed ID: 37244767
[TBL] [Abstract][Full Text] [Related]
5. Investigating Efficient Risk-Stratified Pathways for the Early Detection of Clinically Significant Prostate Cancer.
Morote J; Borque-Fernando Á; Esteban LM; Celma A; Campistol M; Miró B; Méndez O; Trilla E
J Pers Med; 2024 Jan; 14(2):. PubMed ID: 38392564
[TBL] [Abstract][Full Text] [Related]
6. The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis.
Avolio PP; Lughezzani G; Paciotti M; Maffei D; Uleri A; Frego N; Hurle R; Lazzeri M; Saita A; Guazzoni G; Casale P; Buffi NM
Urol Oncol; 2021 Dec; 39(12):832.e1-832.e7. PubMed ID: 34183255
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer.
Lokeshwar SD; Nguyen J; Rahman SN; Khajir G; Ho R; Ghabili K; Leapman MS; Weinreb JC; Sprenkle PC
Urol Oncol; 2022 Sep; 40(9):407.e21-407.e27. PubMed ID: 35811206
[TBL] [Abstract][Full Text] [Related]
8. The additive value of mpMRI on prostate cancer detection: Comparison between patients with and without a suspicious digital rectal examination (DRE).
Omri N; Alex S; Jacob B; Ofer N
Urol Oncol; 2021 Oct; 39(10):728.e7-728.e11. PubMed ID: 33454199
[TBL] [Abstract][Full Text] [Related]
9. Natural History of Patients with Prostate MRI Likert 1-3 and Development of RosCaP: a Multivariate Risk Score for Clinically Significant Cancer.
Orecchia L; Nardi A; Fletcher P; Ippoliti S; Grounds J; Dokubo I; Spicchiale CF; Miah S; Miano R; Barrett T; Kastner C
Clin Genitourin Cancer; 2023 Feb; 21(1):162-170. PubMed ID: 35970760
[TBL] [Abstract][Full Text] [Related]
10. Different diagnostic strategies combining prostate health index and magnetic resonance imaging for predicting prostate cancer: A multicentre study.
Zhu M; Fu Q; Zang Y; Shao Z; Zhou Y; Jiang Z; Wang W; Shi B; Chen S; Zhu Y
Urol Oncol; 2024 May; 42(5):159.e17-159.e23. PubMed ID: 38480077
[TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
13. The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy.
Perrin A; Venderink W; Patak MA; Möckel C; Fehr JL; Jichlinski P; Porcellini B; Lucca I; Futterer J; Valerio M
Urol Oncol; 2021 May; 39(5):297.e9-297.e16. PubMed ID: 33341358
[TBL] [Abstract][Full Text] [Related]
14. Systematic prostate biopsy still matters: A comprehensive analysis of MRI/TRUS-fusion targeted prostate biopsies across different indications.
Westhoff N; Baeßler B; von Hardenberg J; Hetjens S; Porubsky S; Siegel F; Martini T; Michel MS; Attenberger U; Ritter M
Urol Oncol; 2019 Oct; 37(10):678-687. PubMed ID: 31375340
[TBL] [Abstract][Full Text] [Related]
15. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
[TBL] [Abstract][Full Text] [Related]
16. Evolution of Targeted Prostate Biopsy by Adding Micro-Ultrasound to the Magnetic Resonance Imaging Pathway.
Wiemer L; Hollenbach M; Heckmann R; Kittner B; Plage H; Reimann M; Asbach P; Friedersdorff F; Schlomm T; Hofbauer S; Cash H
Eur Urol Focus; 2021 Nov; 7(6):1292-1299. PubMed ID: 32654967
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric MRI in men with clinical suspicion of prostate cancer undergoing repeat biopsy: a prospective comparison with clinical findings and histopathology.
Boesen L; Nørgaard N; Løgager V; Balslev I; Thomsen HS
Acta Radiol; 2018 Mar; 59(3):371-380. PubMed ID: 28679325
[TBL] [Abstract][Full Text] [Related]
18. An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.
Costa DN; Kay FU; Pedrosa I; Kolski L; Lotan Y; Roehrborn CG; Hornberger B; Xi Y; Francis F; Rofsky NM
Urol Oncol; 2017 Apr; 35(4):149.e15-149.e21. PubMed ID: 27939349
[TBL] [Abstract][Full Text] [Related]
19. External validation and comparison of magnetic resonance imaging-based predictive models for clinically significant prostate cancer.
Lee HJ; Lee A; Yang XY; Law YM; Huang HH; Lau WK; Lee LS; Ho HS; Cheng CW; Yuen JS; Tay KJ; Chen K
Urol Oncol; 2021 Nov; 39(11):783.e1-783.e10. PubMed ID: 33775528
[TBL] [Abstract][Full Text] [Related]
20. Surgeon seniority and experience have no effect on CaP detection rates using MRI/TRUS fusion-guided targeted biopsies.
Taha F; Larre S; Branchu B;
Urol Oncol; 2024 Mar; 42(3):67.e1-67.e7. PubMed ID: 38245408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
